Axcella seeks 'light speed' swing at long Covid, but needs cash
In December, Axcella laid off 85% of its workforce and said it was looking for “strategic alternatives,” but for now it’s still pushing forward with its long Covid trial plans.
In an investor call Tuesday morning, Axcella outlined a late-stage trial design. It plans to enroll around 300 patients in a study using a fatigue questionnaire known as the CFQ 11, which it used in its previous Phase II trial, as the primary endpoint. And Axcella said that it’s aligned with UK authorities on that endpoint.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.